Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Fipaxalparant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D known ✓ | Q08499 | 2/20 | 0.40 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561627 | 0.91 | LPAR1 (0.67) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| Fipaxalparant SCHEMBL1560214 | 0.91 | LPAR1 (0.78) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| Fipaxalparant SCHEMBL29382253 | 0.91 | LPAR1 (0.78) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| SCHEMBL29398945 | 0.91 | LPAR1 (0.67) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| Fipaxalparant SCHEMBL29398637 | 0.91 | LPAR1 (0.78) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| SCHEMBL1561405 | 0.91 | LPAR1 (0.67) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| SCHEMBL26242667 | 0.89 | LPAR1 (0.64) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| SCHEMBL26242451 | 0.89 | LPAR1 (0.64) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| SCHEMBL1561481 | 0.88 | LPAR1 (0.78) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| SCHEMBL1560508 | 0.86 | LPAR1 (0.74) | LPAR1HDAC1SMPD1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4486719-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | Horizon Therapeutics Ireland DAC (IE) | 2025-01-08 | — | — | EP | claimed |
| US-20230295073-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-21 | — | — | US | claimed |
| WO-2023166346-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-07 | — | — | WO | claimed |
| US-12391640-B2 | Process of making a crystalline EDG-2 receptor antagonist | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-08-19 | — | — | US | disclosed |
| EP-4486719-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | Horizon Therapeutics Ireland DAC (IE) | 2025-01-08 | — | — | EP | disclosed |
| US-20230295073-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-21 | — | — | US | disclosed |
| WO-2023166346-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295073-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | EDNRA, EDNRB, FFAR2 | PDE4D 993/4885PDE4A 935/4885PDE4B 1096/4885 |
| US-12391640-B2 | Process of making a crystalline EDG-2 receptor antagonist | EDNRA, EDNRB, FFAR2 | PDE4D 993/4885PDE4A 935/4885PDE4B 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.